Risks of Pyridostigmine in Antibody-Negative Myasthenia Gravis vs Steroid-Induced Myopathy

Diagnostic Considerations

Pyridostigmine can be safely initiated at 30 mg orally three times daily in suspected antibody-negative myasthenia gravis, providing diagnostic and therapeutic value with minimal risk if the diagnosis is actually steroid-induced myopathy, where it will simply be ineffective rather than harmful 1, 2
Testing for MuSK and LRP4 antibodies is recommended, as approximately 50% of seronegative myasthenia patients have MuSK antibodies 1
Checking CK, aldolase, ESR, and CRP is necessary to evaluate for concurrent myositis or steroid myopathy 3, 1
Electrodiagnostic studies with repetitive nerve stimulation and/or jitter studies should be performed to confirm neuromuscular junction dysfunction characteristic of myasthenia gravis 1
Assessing pulmonary function with NIF and VC is essential to establish baseline respiratory muscle strength 4, 1

The American College of Neurology recommends starting pyridostigmine at 30 mg orally three times daily and titrating gradually to maximum 120 mg four times daily based on clinical response 1, 2
Clinical improvement within days to weeks supports myasthenia gravis diagnosis 2, 1
Monitoring respiratory function with serial NIF and VC measurements is crucial, especially if bulbar symptoms develop 4, 1
Avoiding medications that worsen myasthenia, such as β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides, is recommended 1, 2

If symptoms persist despite pyridostigmine 120 mg four times daily, adding prednisone 0.5-1.5 mg/kg orally daily may be considered 1, 2
IVIG 2 g/kg IV over 5 days or plasmapheresis may be considered as steroid-sparing alternatives, especially if MuSK-positive 1
Neurology consultation is mandatory for complex cases with diagnostic uncertainty 5, 1